Essendon, Australia Clinical Trials

A listing of Essendon, Australia clinical trials actively recruiting patients volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
I am looking for
added new label for I am looking for
Advanced Filters
Found 68 clinical trials
Study of BGB-A425 in Combination With Tislelizumab in Advanced Solid Tumors

BGB-A425 is a humanized, immunoglobulin gamma-1 (IgG1)-variant monoclonal antibody against TIM-3. Tislelizumab is a humanized, immunoglobulin G4 (IgG4)-variant monoclonal antibody against PD-1. This study tests the safety and anti-tumor effect of BGB-A425 in combination with tislelizumab in participants with advanced solid tumors.

Peter MacCallum Cancer Centre
 (5.2 away) Contact site
  • 19 Jun, 2021
  • +16 other locations
LYT-100 in Healthy Volunteers and BCRL

Part 1 is a multiple ascending dose trial in healthy volunteers (HV) of LYT-100 to determine safety, tolerability, and pharmacokinetic (PK) profile under fed conditions. Part 2 is a single dose safety, tolerability, and PK trial in HV of LYT-100 under fed and fasted conditions. Part 3 is a trial …

breast cancer
compression therapy
secondary lymphedema
Nucleus Network VIC
 (6.7 away) Contact site
  • 12 Apr, 2021
  • +3 other locations
First-in-Human Study of XMT-1536 in Cancers Likely to Express NaPi2b

First-in-human, Phase 1b/2 safety study of the antibody-drug conjugate (ADC) XMT-1536 (upifitamab rilsodotin) administered as an intravenous infusion once every four weeks. Patients with tumor types likely to express NaPi2b were enrolled in dose escalation. Patients with platinum-resistant ovarian cancer and non-small cell lung cancer (adenocarcinoma subtype) are being enrolled …

measurable disease
monoclonal antibodies
lung cancer
programmed cell death 1 ligand 1
Peter MacCallum Cancer Centre
 (5.2 away) Contact site
  • 14 May, 2021
  • +43 other locations
Brief Title: Study of BGB-10188 as Monotherapy and in Combination With Zanubrutinib and Tislelizumab

The purpose of this study is to determine the maximum tolerated dose (MTD), recommended Phase 2 dose(RP2D),safety & tolerability of BGB-10188: as monotherapy in participants with mature B-cell malignancies; oin combination with zanubrutinib in participants with relapse/refractory follicular lymphoma (R/R FL), mantle cell lymphoma (MCL) or diffuse large B-cell lymphoma …

breast cancer
solid tumour
chronic lymphocytic leukemia
solid tumor
mantle cell lymphoma
Austin Hospital - Hematology
 (8.6 away) Contact site
  • 09 Apr, 2021
  • +5 other locations
Dosimetry Safety and Potential Benefit of 177Lu-PSMA-617 Prior to Prostatectomy

This clinical trial will evaluate the dosimetry, efficacy and toxicity of Lu-PSMA in men with high PSMA-expressing high-risk localized or locoregional advanced prostate cancer (HRCaP) undergoing radical prostatectomy (RP) and pelvic lymph node dissection (PLND)

neutrophil count
pet/ct scan
Peter MacCallum Cancer Centre
 (5.4 away) Contact site
  • 25 Jan, 2021
  • 1 location
Study of Adjuvant Immunotherapy With EVX-02 and Anti-PD-1

This is a Phase 1/2, open label, multi-centre study to assess the safety, tolerability, PD, and efficacy of adjuvant immunotherapy EVX-02 vaccine and anti-PD-1 (Nivolumab) in patients who have had a complete resection of a Stage IIIB/IIIC/IIID or Stage IV melanoma who are at high risk of recurrence.

absolute neutrophil count
treatment regimen
metastatic melanoma
complete resection
Peter MacCallum Cancer Centre
 (5.2 away) Contact site
  • 18 Mar, 2021
  • +5 other locations
A Dose Escalation/Expansion Study of Oral OP-1250 in Subjects With Advanced and/or Metastatic HR+ HER2- Breast Cancer

This clinical trial is a Phase 1-2, open-label, multi-center, dose-escalation and expansion study evaluating the safety, pharmacokinetics, pharmacodynamics, and antitumor activity of daily oral administration of OP-1250.

hormone therapy
renal function
Peter MacCallum Cancer Centre
 (5.2 away) Contact site
  • 15 May, 2021
  • +8 other locations
The MEseNchymal coviD-19 Trial: MSCs in Adults With Respiratory Failure Due to COVID-19 or Another Underlying Cause

This is a pilot, multi-centre, open-label randomised controlled study to assess the early efficacy of intravenous (IV) administration of CYP-001 in adults admitted to an intensive care unit (ICU) with respiratory failure

fluid overload
respiratory symptoms
respiratory symptom
Footscray Hospital
 (3.5 away) Contact site
  • 27 May, 2021
  • +3 other locations
Bioimaging Study of 89Zr-M7824 in NSCLC

This is a bioimaging study of 89Zr-M7824 PET scans in patients with advanced or metastatic non-small cell lung cancer who will be receiving M7824 alone or with standard of care chemotherapy. M7824 is a bifunctional fusion protein that combines an anti-PD-L1 antibody and the extracellular domain of TGF receptor II …

measurable disease
lung carcinoma
serum bilirubin level
neutrophil count
cancer chemotherapy
Austin Health
 (6.3 away) Contact site
  • 19 Jul, 2021
  • 1 location
Safety and Efficacy of NPI-001 Tablets for RP Associated With Usher Syndrome

This study will examine the safety and efficacy of NPI-001 Tablets as compared to placebo for 24 months in subjects with vision loss due to RP associated with Usher syndrome.

usher syndrome
 (5.2 away) Contact site
  • 04 Jul, 2021
  • +3 other locations